Related Experiment Video

Updated: Jul 12, 2026

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells
09:12

MISSION LentiPlex Pooled shRNA Library Screening in Mammalian Cells

Published on: December 21, 2011

Iclaprim

Stephan A Kohlhoff1, Roopali Sharma

  • 1State University of New York Downstate Medical Center, Department of Pediatrics, Division of Pediatric Infectious Diseases, Brooklyn, NY 11203, USA. stephan.kohlhoff@downstate.edu

Expert Opinion on Investigational Drugs
|August 24, 2007
PubMed

Insights

Iclaprim shows strong in vitro activity against resistant Gram-positive bacteria, including MRSA. Clinical trials suggest its potential as a new oral and IV antibiotic for skin infections.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Bacteriology

Background:

  • Iclaprim is a novel diaminopyrimidine and dihydrofolate reductase inhibitor.
  • It exhibits potent, extended-spectrum in vitro activity against various resistant bacteria.

Purpose of the Study:

  • To evaluate the efficacy and pharmacokinetic profile of iclaprim.
  • To assess its potential as a novel antibiotic for complicated skin and skin structure infections and respiratory infections.

Main Methods:

  • In vitro susceptibility testing against resistant bacterial strains.
  • Pharmacokinetic profiling for intravenous and oral administration.
  • Phase II and Phase III clinical trials for complicated skin and skin structure infections.

Main Results:

  • Potent in vitro activity against Gram-positive bacteria (including resistant strains of S. aureus and S. pneumoniae) and some Gram-negative and atypical bacteria.
  • Favorable pharmacokinetic profile with good oral bioavailability, suitable for IV and oral use.
  • Promising results from Phase II trials for complicated skin and skin structure infections; two Phase III trials completed.

Conclusions:

  • Iclaprim demonstrates significant potential as a new antibiotic for treating infections caused by resistant bacteria.
  • Its pharmacokinetic profile supports both parenteral and oral administration.
  • Further clinical development is ongoing for respiratory infections.

More Related Videos

Visualization of Replisome Encounters with an Antigen Tagged Blocking Lesion08:24

Visualization of Replisome Encounters with an Antigen Tagged Blocking Lesion

Published on: July 27, 2021

Field-Deployable Candidatus Liberibacter asiaticus Detection Using Recombinase Polymerase Amplification Combined with CRISPR-Cas12a09:03

Field-Deployable Candidatus Liberibacter asiaticus Detection Using Recombinase Polymerase Amplification Combined with CRISPR-Cas12a

Published on: December 23, 2022

Related Concept Videos

The Replisome03:01

The Replisome

DNA replication is carried out by a large complex of proteins that act in a coordinated matter to achieve high-fidelity DNA replication. Together this complex is known as the DNA replication machinery or the replisome.
The synthesis of the leading and lagging strands is a highly coordinated process. To explain this, the “Trombone model” was proposed by Bruce Alberts in 1980. The DNA loop formation starts when a primer is synthesized on the parent lagging strand. The loop grows with the...
Hand hygiene01:23

Hand hygiene

Asepsis is the practice of preventing or breaking the chain of infection. The nurse employs aseptic techniques to prevent the spread of microorganisms and reduce the risk of diseases. Hand hygiene is the cornerstone of aseptic techniques and is classified into medical and surgical asepsis. Medical asepsis includes hand hygiene and the use of gloves. Surgical asepsis, or the sterile technique, refers to practices that render and keep objects and areas free of microorganisms.
Hand washing...
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.